Suppr超能文献

口服羟考酮/纳洛酮与普瑞巴林对肺癌伴神经性疼痛患者的镇痛效果及耐受性:一项观察性分析

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis.

作者信息

De Santis Stefano, Borghesi Cristina, Ricciardi Serena, Giovannoni Daniele, Fulvi Alberto, Migliorino Maria Rita, Marcassa Claudio

机构信息

Palliative Care and Cancer Pain Service, Oncological Pulmonary Unit.

Oncological Pulmonary Unit, San Camillo-Forlanini Hospitals, Rome.

出版信息

Onco Targets Ther. 2016 Jul 4;9:4043-52. doi: 10.2147/OTT.S108144. eCollection 2016.

Abstract

INTRODUCTION

Cancer-related pain has a severe negative impact on quality of life. Combination analgesic therapy with oxycodone and pregabalin is effective for treating neuropathic cancer pain. We investigated the efficacy and tolerability of a dose-escalation combination therapy with prolonged-release oxycodone/naloxone (OXN-PR) and pregabalin in patients with non-small-cell lung cancer and severe neuropathic pain.

METHODS

This was a 4-week, open-label, observational study. Patients were treated with OXN-PR and pregabalin. Average pain intensity ([API] measured on a 0-10 numerical rating scale) and neuropathic pain (Douleur Neuropathique 4) were assessed at study entry and at follow-up visits. The primary endpoint was response to treatment, defined as a reduction of API at T28 ≥30% from baseline. Secondary endpoints included other efficacy measures, as well as patient satisfaction and quality of life (Brief Pain Inventory Short Form), Hospital Anxiety and Depression Scale, and Symptom Distress Scale; bowel function was also assessed.

RESULTS

A total of 56 patients were enrolled. API at baseline was 8.0±0.9, and decreased after 4 weeks by 48% (4.2±1.9; P<0.0001 vs baseline); 46 (82.1%) patients responded to treatment. Significant improvements were also reported in number/severity of breakthrough cancer pain episodes (P=0.001), Brief Pain Inventory Short Form (P=0.0002), Symptom Distress Scale (P<0.0001), Hospital Anxiety and Depression Scale depression (P=0.0006) and anxiety (P<0.0001) subscales, and bowel function (P=0.0003). At study end, 37 (66.0%) patients were satisfied/very satisfied with the new analgesic treatment. Combination therapy had a good safety profile.

CONCLUSION

OXN-PR and pregabalin were safe and highly effective in a real-world setting of severe neuropathic cancer pain, with a high rate of satisfaction, without interference on bowel function.

摘要

引言

癌症相关疼痛对生活质量有严重负面影响。羟考酮和普瑞巴林联合镇痛疗法对治疗神经性癌痛有效。我们研究了缓释羟考酮/纳洛酮(OXN-PR)和普瑞巴林剂量递增联合疗法在非小细胞肺癌伴严重神经性疼痛患者中的疗效和耐受性。

方法

这是一项为期4周的开放标签观察性研究。患者接受OXN-PR和普瑞巴林治疗。在研究开始时和随访时评估平均疼痛强度([API]采用0至10数字评分量表测量)和神经性疼痛(神经病理性疼痛4)。主要终点是治疗反应,定义为T28时API较基线降低≥30%。次要终点包括其他疗效指标,以及患者满意度和生活质量(简明疼痛问卷简表)、医院焦虑抑郁量表和症状困扰量表;还评估了肠道功能。

结果

共纳入56例患者。基线时API为8.0±0.9,4周后降低了48%(4.2±1.9;与基线相比P<0.0001);46例(82.1%)患者对治疗有反应。在突破性癌痛发作的次数/严重程度(P=0.001)、简明疼痛问卷简表(P=0.0002)、症状困扰量表(P<0.0001)、医院焦虑抑郁量表抑郁(P=0.0006)和焦虑(P<0.0001)子量表以及肠道功能(P=0.0003)方面也报告了显著改善。在研究结束时,37例(66.0%)患者对新的镇痛治疗感到满意/非常满意。联合疗法具有良好的安全性。

结论

在严重神经性癌痛的现实环境中,OXN-PR和普瑞巴林安全且高效,满意度高,对肠道功能无干扰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae4b/4938136/44029bff6a46/ott-9-4043Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验